Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity

Nat Immunol. 2021 Jun;22(6):746-756. doi: 10.1038/s41590-021-00940-2. Epub 2021 May 24.

Abstract

T cell exhaustion presents one of the major hurdles to cancer immunotherapy. Among exhausted CD8+ tumor-infiltrating lymphocytes, the terminally exhausted subset contributes directly to tumor cell killing owing to its cytotoxic effector function. However, this subset does not respond to immune checkpoint blockades and is difficult to be reinvigorated with restored proliferative capacity. Here, we show that a half-life-extended interleukin-10-Fc fusion protein directly and potently enhanced expansion and effector function of terminally exhausted CD8+ tumor-infiltrating lymphocytes by promoting oxidative phosphorylation, a process that was independent of the progenitor exhausted T cells. Interleukin-10-Fc was a safe and highly efficient metabolic intervention that synergized with adoptive T cell transfer immunotherapy, leading to eradication of established solid tumors and durable cures in the majority of treated mice. These findings show that metabolic reprogramming by upregulating mitochondrial pyruvate carrier-dependent oxidative phosphorylation can revitalize terminally exhausted T cells and enhance the response to cancer immunotherapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anion Transport Proteins / genetics
  • Anion Transport Proteins / metabolism
  • Cell Line, Tumor
  • Combined Modality Therapy / methods
  • Disease Models, Animal
  • Drug Synergism
  • Female
  • HEK293 Cells
  • Half-Life
  • Humans
  • Immune Checkpoint Inhibitors / pharmacology
  • Immune Checkpoint Inhibitors / therapeutic use
  • Immunoglobulin Fc Fragments / pharmacology
  • Immunoglobulin Fc Fragments / therapeutic use
  • Immunotherapy, Adoptive / methods*
  • Interleukin-10 / pharmacology*
  • Interleukin-10 / therapeutic use
  • Mice
  • Mice, Transgenic
  • Mitochondria / drug effects
  • Mitochondria / metabolism
  • Mitochondrial Membrane Transport Proteins / genetics
  • Mitochondrial Membrane Transport Proteins / metabolism
  • Monocarboxylic Acid Transporters / genetics
  • Monocarboxylic Acid Transporters / metabolism
  • Neoplasms / immunology
  • Neoplasms / pathology
  • Neoplasms / therapy*
  • Oxidative Phosphorylation / drug effects*
  • Receptors, Chimeric Antigen / immunology
  • Receptors, Chimeric Antigen / metabolism
  • Receptors, Interleukin-10 / metabolism
  • Recombinant Fusion Proteins / pharmacology
  • Recombinant Fusion Proteins / therapeutic use
  • Signal Transduction / drug effects
  • Signal Transduction / immunology
  • T-Lymphocytes, Cytotoxic / cytology
  • T-Lymphocytes, Cytotoxic / drug effects*
  • T-Lymphocytes, Cytotoxic / immunology
  • T-Lymphocytes, Cytotoxic / metabolism

Substances

  • Anion Transport Proteins
  • IL10 protein, human
  • Immune Checkpoint Inhibitors
  • Immunoglobulin Fc Fragments
  • MPC1 pyruvate carrier protein, mouse
  • Mitochondrial Membrane Transport Proteins
  • Monocarboxylic Acid Transporters
  • Receptors, Chimeric Antigen
  • Receptors, Interleukin-10
  • Recombinant Fusion Proteins
  • Interleukin-10